KPV for Inflammatory Bowel Disease & Gut Inflammation — Gut
Anti-inflammatory tripeptide for IBD with strong PRECLINICAL evidence in mouse models. NO FDA approval, NO human clinical trials.
Overview
KPV (Lys-Pro-Val) is a C-terminal tripeptide derived from alpha-MSH with potent anti-inflammatory properties. CRITICAL EVIDENCE STATUS: NO FDA approval. ZERO human clinical trials published. Strong preclinical evidence in MOUSE MODELS of IBD (DSS- and TNBS-induced colitis) showed reduced inflammation, decreased MPO activity, and lower pro-inflammatory cytokines. KEY MECHANISM: Anti-inflammatory effect is PepT1-mediated (NOT melanocortin receptor); colonic PepT1 is upregulated in IBD, providing unique targeting opportunity. Nanoparticle delivery systems successfully target colonic epithelial cells and macrophages in animal models. Also shows antimicrobial activity against S. aureus and C. albicans in vitro. NO established human dosing guidelines. NO long-term human safety data. Available only through compounding/research channels. Anyone using KPV is participating in uncontrolled human experimentation.
Indications
- Inflammatory bowel disease (IBD - Crohn's, ulcerative colitis) - PRECLINICAL DATA ONLY
- Chronic gut inflammation and colitis - based on mouse studies
- Leaky gut syndrome and intestinal permeability - theoretical, no human trials
- Post-antibiotic gut dysbiosis - extrapolated from mechanism
- IBS with inflammatory component - no direct evidence
Mechanism of Action
IBD, colitis, or autoimmune gut conditions create persistent inflammation damaging intestinal mucosa
Dosing
| Compound | Dose | Frequency | Notes |
|---|---|---|---|
| KPV (compounded) | 500-1000 mcg | Twice daily on empty stomach | EXTRAPOLATED - no human dosing guidelines; targets gut via PepT1 |
| KPV (compounded) | 500-1000 mcg | Once or twice daily | EXTRAPOLATED - higher bioavailability for systemic effects |
| KPV (compounded) | 1-2 mg | Once or twice daily | THEORETICAL - direct delivery for distal colitis |
Evidence Grade
GRADE D
Safety & Contraindications
- CRITICAL: NO FDA approval; NO published human clinical trials
- All efficacy data from MOUSE MODELS and in vitro studies only
- No established human dosing guidelines - all doses are extrapolated
- No long-term human safety data available
- Available only via compounding/research channels (no FDA quality oversight)
- Pediatric, elderly, and immunocompromised populations NOT studied
- KPV is naturally derived with no notable toxicity in animal studies
- Use of KPV constitutes uncontrolled human experimentation